ReviewCureus2024
Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a significant global health issue, with early detection playing a critical role in improving patient outcomes. The treatment landscape for advanced non-small cell lung cancer (NSCLC) has evolved substantially, especially with the introduction of targeted therapies such as osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI). This narrative review examines the impact of osimertinib on survival rates in early-stage lung cancer and underscores the importance of early diagnosis and treatment initiation. We explore the genetic underpinnings of NSCLC, focusing on the role of EGFR mutations, and discuss the prevalence of early-stage lung cancer and the urgent need for timely intervention. Additionally, the review assesses osimertinib's safety and efficacy in patients with early-stage EGFR-mutated lung cancer, drawing from a wide range of studies and clinical trials. Findings suggest that osimertinib has the potential to improve overall survival (OS) and progression-free survival (PFS) compared to traditional treatments such as chemotherapy, surgery, and first-generation EGFR-TKIs. The therapeutic profile of osimertinib is comprehensively analyzed, including its associated adverse events, clinical outcomes, and its impact on quality of life. We also address potential challenges with osimertinib, such as resistance mechanisms and the need for personalized treatment approaches. Despite these challenges, osimertinib emerges as a promising and well-tolerated treatment option for patients with EGFR mutations in early-stage lung cancer. The review highlights the importance of incorporating osimertinib into standard treatment regimens to improve patient outcomes and survival rates in early-stage lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.